Section Arrow
EYPT.NASDAQ
- EyePoint Inc.
Quotes are at least 15-min delayed:2026/04/07 11:06 EDT
Regular Hours
Last
 12.875
-0.235 (-1.79%)
Day High 
13.1299 
Prev. Close
13.11 
1-M High
16.14 
Volume 
170.08K 
Bid
12.85
Ask
12.88
Day Low
12.57 
Open
12.98 
1-M Low
11.82 
Market Cap 
1.09B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 12.83 
20-SMA 13.48 
50-SMA 14.46 
52-W High 19.11 
52-W Low 5.14 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.17/-4.21
Enterprise Value
1.11B
Balance Sheet
Book Value Per Share
3.67
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
31.37M
Operating Revenue Per Share
0.51
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
LNAILunai Bioworks Inc.0.3941+0.1121+39.75%-- 
SILOSilo Pharma0.5217+0.1659+46.63%-- 
CUECue Biopharma0.17855+0.00155+0.88%-- 
TERNTerns Pharmaceuticals52.625-0.155-0.29%-- 
QNCXQuince Therapeutics0.0986+0.0111+12.69%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.